Prevention of the hypercontractile response to thrombin by proteinase-activated receptor-1 antagonist in subarachnoid hemorrhage

Stroke

Volumn 38, Issue 12, 2007, Pages 3259-3265

  Kai, Yasutoshi ^a   Hirano, Katsuya ^a   Maeda, Yoshihisa ^a   Nishimura, Junji ^a   Sasaki, Tomio ^a   Kanaide, Hideo ^a,b  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Antagonist; Receptors; Thrombin; Vasospasm

Indexed keywords

CALCIUM ION; E 5555; ENDOTHELIN 1; POTASSIUM ION; PROTEINASE ACTIVATED RECEPTOR 1; PYRIDINE DERIVATIVE; THROMBIN; TRYPSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; BASILAR ARTERY; CALCIUM CELL LEVEL; CONTROLLED STUDY; DRUG EFFECT; EX VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; SUBARACHNOID HEMORRHAGE;

ANIMALS; DISEASE MODELS, ANIMAL; FLUOROMETRY; FURA-2; GENE EXPRESSION REGULATION; IMMUNOBLOTTING; MUSCLE CONTRACTION; MYOCYTES, SMOOTH MUSCLE; RABBITS; REACTIVE OXYGEN SPECIES; RECEPTOR, PAR-1; SUBARACHNOID HEMORRHAGE; THROMBIN; VASOCONSTRICTION; VASOSPASM, INTRACRANIAL;

EID: 36448986049     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.487769     Document Type: Article

References (32)

1. Shibuya M, Suzuki Y, Sugita K, Saito I, Sasaki T, Takakura K, Nagata I, Kikuchi H, Takemae T, Hidaka H, Nakashima M. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg. 1992;76:571-577.
2. Sasaki T, Wakai S, Asano T, Takakura K, Sano K. Prevention of cerebral vasospasm after SAH with a thromboxane synthetase inhibitor, OKY-1581. J Neurosurg. 1982;57:74-82.
3. Suzuki S, Sano K, Handa H, Asano T, Tamura A, Yonekawa Y, Ono H, Tachibana N, Hanaoka K. Clinical study of OKY-046, a thromboxane synthetase inhibitor, in prevention of cerebral vasospasms and delayed cerebral ischaemic symptoms after subarachnoid haemorrhage due to aneurysmal rupture: a randomized double-blind study. Neurol Res. 1989;11:79-88.
4. Feigin VL, Rinkel GJE, Algra A, Vermeulen M, Gijin JV. Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage. Neurology. 1998;50:876-883.
5. Kaku Y, Yonekawa Y, Tsukahara T, Kazekawa K. Superselective intra-arterial infusion of papaverine for the treatment of cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg. 1992;77:842-847.
6. Asano T. Oxyhemoglobin as the principal cause of cerebral vasospasm: a holistic view of its actions. Crit Rev Neurosurg. 1999;9:303-318.
7. Sasaki T, Wakai S, Asano T, Watanabe T, Kirino T, Sano K. The effect of a lipid hydroperoxide of arachidonic acid on the canine basilar artery: an experimental study on cerebral vasospasm. J Neurosurg. 1981;54:357-365.
8. Kim DE, Suh YS, Lee MS, Kim KY, Lee JH, Lee HS, Hong KW, Kim CD. Vascular NAD(P)H oxidase triggers delayed cerebral vasospasm after subarachnoid hemorrhage in rats. Stroke. 2002;33:2687-2691.
9. Voldby B, Engbaek F, Enevoldsen EM. CSF serotonin concentrations and cerebral arterial spasm in patients with ruptured intracranial aneurysm. Stroke. 1982;13:184-189.
10. Itoh S, Sasaki T, Asai A, Kuchino Y. Prevention of delayed vasospasm by an endothelin ETA receptor antagonist, BQ-123: change of ETA receptor mRNA expression in a canine subarachnoid hemorrhage model. J Neurosurg. 1994;81:759-764.
11. Lobato R, Marin J, Salaices M, Rico M, Sanchez C. Effect of subarachnoid hemorrhage on contractile responses and noradrenaline release evoked in cat cerebral arteries by histamine. J Neurosurg. 1981;55:543-549.
12. Kasuya H, Shimizu T, Takakura K. Thrombin activity in CSF after SAH is correlated with the degree of SAH, the persistence of subarachnoid clot and the development of vasospasm. Acta Neurochir (Wien). 1998;140:579-584.
13. Tsurutani H, Ohkuma H, Suzuki S. Effects of thrombin inhibitor on thrombin-related signal transduction and cerebral vasospasm in the rabbit subarachnoid hemorrhage model. Stroke. 2003;34:1497-1500.
14. Saito I, Ueda Y, Sano K. Significance of vasospasm in the treatment of ruptured intracranial aneurysms. J Neurosurg. 1977;47:412-429.
15. Sano K, Saito I. Timing and indication of surgery for ruptured intracranial aneurysms with regard to cerebral vasospasm. Acta Neurochir (Wien). 1978;41:49-60.
16. Inagawa T, Yamamoto M, Kamiya K. Effect of clot removal on cerebral vasospasm. J Neurosurg. 1990;72:224-230.
17. Hirano K, Kanaide H. Role of protease-activated receptors in the vascular system. J Atheroscler Thromb. 2003;10:211-225.
18. Hollenberg MD. Physiology and pathophysiology of proteinase-activated receptors (PARs): proteinases as hormone-like signal messengers: PARs and more. J Pharmacol Sci. 2005;97:8-13.
19. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev. 2001;53:245-282.
20. Kogushi M, Kobayashi H, Matsuoka T, Suzuki S, Kawahara T, Kajiwara A, Hishinuma L. Anti-thrombotic and bleeding time effects of E5555, an orally active protease-activated receptor-1 antagonist, in guinea pigs. Circulation. 2003;108:280.
21. Matsuoka T, Kogushi M, Kawata T, Kimura A, Chiba K, Musha T, Kobayashi H, Kawahara T, Suzuki S, Kajiwara A, Hishinuma L. Inhibitory effect of E5555, an orally active thrombin receptor antagonist, on intimal hyperplasia following balloon injury. J Am Coll Cardiol. 2004;43:68A-68A.
22. 2+ sensitivity in the bovine middle cerebral artery. Br J Pharmacol. 2003;140:871-880.
23. Yufu T, Hirano K, Bi D, Hirano M, Nishimura J, Iwamoto Y, Kanaide H. Rac1 regulation of surface expression of protease-activated receptor-1 and responsiveness to thrombin in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2005;25:1506-1511.
24. i in smooth muscle strips using frontsurface fluorometry. In: Lambert DG, ed. Methods of Molecular Biology. Totowa, NJ: Humana Press; 1999:269-277.
25. i-linked Ras/mitogen-activated protein kinase pathway. J Biol Chem. 1999;274:13718-13727.
26. McLaughlin JN, Mazzoni MR, Cleator JH, Earls L, Perdigoto AL, Brooks JD, Muldowney JA 3rd, Vaughan DE, Hamm HE. Thrombin modulates the expression of a set of genes including thrombospondin-1 in human microvascular endothelial cells. J Biol Chem. 2005;280:22172-22180.
27. Mizuno O, Hirano K, Nishimura J, Kubo C, Kanaide H. Proteolysis and phosphorylation-mediated regulation of thrombin receptor activity in in situ endothelial cells. Eur J Pharmacol. 2000;389:13-23.
28. Nakayama T, Hirano K, Hirano M, Nishimura J, Kuga H, Nakamura K, Takahashi S, Kanaide H. Inactivation of protease-activated receptor-1 by proteolytic removal of the ligand region in vascular endothelial cells. Biochem Pharmacol. 2004;68:23-32.
29. Dery O, Corvera CU, Steinhoff M, Bunnett NW. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol. 1998;274:C1429-1452.
30. Trejo J. Protease-activated receptors: new concepts in regulation of G protein-coupled receptor signaling and trafficking. J Pharmacol Exp Ther. 2003;307:437-442.
31. Steinberg SF. The cardiovascular actions of protease-activated receptors. Mol Pharmacol. 2005;67:2-11.
32. Andrade-Gordon P, Derian CK, Maryanoff BE, Zhang H-C, Addo MF, Cheung W-M, Damiano BP, D'Andrea MR, Darrow AL, de Garavilla L, Eckardt AJ, Giardino EC, Haertlein BJ, McComsey DF. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J Pharmacol Exp Ther. 2001;298:34-42.